Abstract
Although considerable progress has been made in elucidating the mechanism of atopoic dermatitis [AD], the cellular and molecular mechanisms regulating AD still remains obscure. Recently, IgE mediated late phase reaction is thought to be mainly associated with the pathogenesis of AD. We have established the eczematous skin reaction induced by anti-DNP-IgE antibody and DNFB in AD model mouse. STAT6 is known as a regulator of IL-4- dependent immune responses. We have also established STAT6 deficient mice and concluded that STAT6 plays a crucial role in exerting IL-4 and IL-13 mediated biological responses. On the basis of these earlier studies, we have developed novel therapy for AD using STAT6 Decoy ODN that clearly downregulated late phase cutaneous response of IgE mediated biphasic reactions, which is now thought to be closely related to skin reactions seen in human AD. Although a number of important issues, such as the safety and side effects, have not yet been addressed in this study, the decoy strategy against STAT6 may provide a new therapeutic modality as gene therapy against AD. In a preliminary study, we applied STAT6 decoy ointment to the refractory AD after ethical approval. Significant improvements of skin scores and pruritis were obtained in four cases. Large scale clinical studies are under way and will provide much more information about the proper clinical use, indications and side effects and usefulness in daily clinical practice in the near future
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Katayama I, Tanei R, Nishioka K, et al. (1990). Induction of eczematous skin reaction in experimentally induced hyperplastic skin of Balb/c mice by monoclonal anti-DNP-IgE antibody: Possible implication for skin lesion formation in atopic dermatitis. Int Arch Allergy Appl Immunol 93, 148–154
Yokozeki H, Ghoreishi M, Takagawa S, et al. (2000). Signal transduccer and activator of Transcription 6 is essential in the induction of contact hypersensitivity. J Exp Med 191, 995–1004
Takeda K, Tanaka T, Shi W, et al. (1996). Essential role of Stat6 in IL-4 signaling. Nature 380, 627–630
Taked K, Tanaka M, Tanaka T, et al. (1996). Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 157, 3220–3222
Morishita R, Gibbons GH, Horiuchi M, et al. (1995). A gene Therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth proliferation in vivo. Proc Natl Acad USA 92, 5855–5859
Morishita R, Higaki J, et al. (1996). Role of transcriptional cis-elements, angiotensinogen gene-activating element, of angiotensinogen genein blood pressure regulation. Hypertension 27, 502–507
Morishita R, Sugimoto T, Aoki M, et al. (1997). On vivo transfection of cis element decoy against nuclear factor-kB binding site prevents myocardial infection. Nature Med 3, 894–899
Nakamura H, Aoki M, Tamai K, et al. (2002). Prevention and regulation of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 9, 1221–1229
Abeyama K, Eng W, Jester JV, Vink AA (2000). A role for NF-kB dependent gene transaction in sunburn. J Clin Invest 105, 1751–1759
Wang LH, Yang X Y, Kirken RA, et al. (2000). Targeted disruption of Stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-deriven Th2 cell response. Blood 95, 1249–1257
McLean WH, Hull PR (2007). Breach delivery: increased solute uptake points to a defective skin barrier in atopic dermatitis. J Invest Dermatol 127, 8–10
Bieber T (1994). Fc epsilon RI on human Langerhans cells: a receptor in search of new functions. Immunol Today 15, 52–53
Yokozeki H, Takayama K, Ohki O, et al. (1998). Comparative analysis of CD80 and CD86 on human Langerhans cells: expression and function. Arch Dermatol Res 290, 547–552
Ohki O, Yokozeki H, Katayama I, et al. (1997). Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis. Br J Dermatol 136, 838–845
Agnello D, Lankford CS, Bream J, et al. (2003). Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 23, 147–161
Ozaki A, Ishida WK, Fukata K, et al. (2004). Detection of antigen-specific T cells in experimental immune-mediated blepharoconjunctivitis in DO11.10 T cell receptor transgenic mice. Microbiol Immunol 48, 39–48
Horiuchi Y, S-J Bae, Katayama I (2005). Overexpression of the suppressor of cytokine signalling 3 (SOCS3) in severe atopic dermatitis. Clin Exp Dermatol 31, 100–104
Horiuchi Y, Bae S, Katayama I, et al. (2006). Lipoteichoic acid-related molecule derived from the streptococcal preparation, OK-432, which suppresses atopic dermatitis-like lesions in NC/ Nga mice. Arch Dermatol Res 298, 163–173
Elbe-Burger A, Egyed A, Olt S, et al. (2002). Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol 118, 767–778
Konishi H, Tsutsui H, Murakami T, et al. (2002). IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc Natl Acad Sci USA 99, 11340–11345
Shiohara T, Hayakawa J, Mizukawa Y (2004). Animal models for atopic dermatitis: are they relevant to human disease? J Dermatol Sci 36, 1–9
Molitor JA, Walker WH, Doerre S, et al. (1990). NF-kB: a family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proc Natl Acad Sci USA 1990 87, 10028–10032
Kaneda Y, Iwaki K, Uchida T (1989). Introduction of the human insulin gene in adult rat liver. J Biol Chem 264, 12126–12129
Yokozeki H, Wu MH, Sumi K, et al. (2004). In vivo transfection of a cis element decoy against signal transducers and activators of transcription 6 (STAT6)-binding site ameliorates IgE-mediated late-phase reaction in an atopic dermatitis mouse model. Gene Ther 11, 1753–1762
Yagi R, Nagai H, Iigo Y, et al. (2002). Development of atopic dermatitis-like lesions inSTAT6-deficient NC/Nga mice. J Immunol 168, 2020–2027
Malaviya R and Uckun MF (2002). Role of STAT6 in IgE receptor/FceRI- mediated late phase allegic response of mast cells. J Immunol 168, 421–426
Bruijnzeel PL, Kuijper PH, Kapp A, et al. (1993). The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic dermatitis. Clin Exp Allergy 23, 97–109
Sampson HA (1988). The role of food allergy and mediator release in atopic dermatitis. J Allergy Clin Immunol 81, 635–645
Rajka G (1988) Pathomechanism. Genetic and immunological factors, In Essential Aspects of Atopic Deramatitis. Tokyo, Springer, pp 108–111
Igawa K, Satoh T, Yokozeki H (2009). A therapeutic effect of STAT6 decoy oligodeoxynucleo-tide ointment in atopic dermatitis: a pilot study in adults. Br J Dermatol 160, 1124–1126
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer
About this chapter
Cite this chapter
Katayama, I., Murota, H., Igawa, K., Satoh, T., Nishioka, K., Yokozeki, H. (2010). Targeting STAT6 in Atopic Eczema/Dermatitis. In: Pawankar, R., Holgate, S.T., Rosenwasser, L.J. (eds) Allergy Frontiers: Future Perspectives. Allergy Frontiers, vol 6. Springer, Tokyo. https://doi.org/10.1007/978-4-431-99365-0_10
Download citation
DOI: https://doi.org/10.1007/978-4-431-99365-0_10
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-99364-3
Online ISBN: 978-4-431-99365-0
eBook Packages: MedicineMedicine (R0)